Skip to the content
  • Our Company
    • Management Team
    • Board Members
    • Events
  • Our Approach
  • Partner
  • Careers
  • Resources
  • News
Menu
  • Our Company
    • Management Team
    • Board Members
    • Events
  • Our Approach
  • Partner
  • Careers
  • Resources
  • News
  • Contact
Menu
  • Contact

Nimble Announces Collaboration to Discover and Develop Novel Peptide-Based Compounds for SARS-CoV-2 Diagnostics

read more
Path 3
  • Press Release
  • May 6, 2020

Madison, WI, USA. May 6, 2020 — Nimble Therapeutics, Inc. today announced a collaboration with Roche Diagnostics to accelerate discovery of novel peptide-based molecules for the development of SARS-CoV-2 in vitro diagnostic assays.

Nimble will extend its proprietary peptide synthesis, screening and optimization platform to enable faster discovery and optimization of promising compounds for detecting SARS-CoV-2. Roche will leverage its world-class capabilities to develop in vitro diagnostic assays for rapid detection of SARS-CoV-2.

“We are extremely motivated to partner with Roche to tackle this global COVID-19 health crisis” said Jigar Patel, Ph.D., Chief Executive Officer of Nimble Therapeutics. “This partnership expands our discovery capabilities, demonstrating the power and breadth of the Nimble platform in rapidly discovering novel compounds.”

Terms of the agreement are not being disclosed.

PreviousNimble & Svar Life Science Announce Collaboration to Discover, Develop and Commercialize Diagnostic Tests based on Nimble’s Novel Biomarker Discovery Engine
NextProtease-activation using anti-idiotypic masks enables tumor specificity of a folate receptor 1-T cell bispecific antibody.
PreviousNimble & Svar Life Science Announce Collaboration to Discover, Develop and Commercialize Diagnostic Tests based on Nimble’s Novel Biomarker Discovery Engine
NextProtease-activation using anti-idiotypic masks enables tumor specificity of a folate receptor 1-T cell bispecific antibody.
  • Our Company
  • Our Approach
  • Partner
  • Careers
  • Resources
  • Contact
  • Our Company
  • Our Approach
  • Partner
  • Careers
  • Resources
  • Contact
  • Our Company
  • Our Approach
  • Partner
  • Careers
  • Resources
  • Contact
  • Our Company
  • Our Approach
  • Partner
  • Careers
  • Resources
  • Contact

603 Science Dr
Madison, WI, USA 53711

LinkedIn
  • Nimble Therapeutics Announces Expansion of its Discovery and Development Partnership with Genentech
    Read More